Ufp Technologies Inc (UFPT) · Nov 3, 2026 · Earnings
Beat — Adjusted EPS $2.88 vs roughly $2.5 consensus
UFP Technologies earnings beat on 11.1% organic growth and expanding margins, though execution issues in the Dominican Republic remain unresolved.
UFP Technologies is a medical-device contract manufacturer pursuing growth through MedTech outsourcing, acquisitions, and a broader low-cost manufacturing footprint. Its recent strategy has emphasized adding capabilities through acquisitions while expanding capacity in the Dominican Republic and other international locations.
The quarter cleared the market’s bar by a useful margin. Published estimates varied, but clustered around roughly $2.5 of adjusted EPS and $166–170 million of revenue; UFP delivered $2.88 and $172.4 million. Revenue growth was not just acquisition-driven: management reported 11.1% organic growth, while MedTech sales rose 12.5%. 〔0〕 〔1〕
| Metric | Q3 2026 | Q3 2025 | Consensus / comparison |
|---|---|---|---|
| Net sales (Financial Statements) | $172.4M (+11.6%) | $154.6M | ≈$166–170M |
| Adjusted diluted EPS (Non-GAAP EPS reconciliation) | $2.88 (+20.5%) | $2.39 | ≈$2.5 |
| Organic sales growth (Organic sales reconciliation) | 11.1% | 7.9% | |
| Gross margin (Financial Highlights) | 29.4% | 27.7% | |
| Adjusted operating income (Non-GAAP reconciliation) | $30.1M (+14.5%) | $26.3M | |
| Adjusted SG&A as % of sales (Adjusted SG&A reconciliation) | 12.0% | 10.7% |
The quality of growth improved, but the cost structure is still unfinished. Gross margin expanded 170 basis points and adjusted operating income grew 14.5%, showing that UFP is converting strong demand into incremental profit. The offset is that adjusted SG&A rose to 12.0% of sales from 10.7%, so overhead is growing faster than the business and blunts the operating leverage story. 〔2〕
Execution remains ahead overall, not cleanly ahead everywhere. UFP says its TPI investment has exceeded expectations and that AJR has made significant progress, but scheduled program transfers to the Dominican Republic and margin improvement remain behind plan. That caveat matters because the Dominican Republic footprint is meant to support both capacity expansion and better economics; the quarter validates demand, but not yet the full operating model. 〔3〕
The balance sheet gives the growth strategy more room. Long-term debt fell to $83.5 million from $123.0 million at year-end while nine-month adjusted EBITDA reached $102.8 million, and management is pursuing a larger credit facility to fund additional acquisitions. That is supportive of the acquisition-led plan, although the facility expansion and prospective deals are not completed events yet. 〔4〕
Bottom line: This was a genuine earnings beat with strong organic MedTech demand and better gross margins, modestly strengthening UFP’s growth story. The main limitation is that overhead, Dominican program transfers, and margin execution still need to catch up with the company’s ambition.
Credit facility expansion and acquisition updates
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!